Dr. Reddy’s Laboratories (NYSE: RDY) — Perfil da empresa, notícias e dados financeiros
Dr. Reddy’s Laboratories is a global pharmaceutical company providing affordable medicines across various therapeutic areas.
Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is a global pharmaceutical company headquartered in India that operates across four primary business segments: Generics, Active Pharmaceutical Ingredients (API) & Services, Innovative Medicines, and Consumer Health. The company develops, manufactures, and markets generic pharmaceuticals, active pharmaceutical ingredients, biosimilars, and over-the-counter health solutions globally. Its product portfolio spans major therapeutic areas including oncology, gastroenterology, cardiovascular, central nervous system, and pain management. Dr. Reddy’s Laboratories commercializes its products across major global markets including India, North America, Europe, and various emerging markets through internal development, manufacturing capabilities, and strategic global partnerships.
Resumo
Operações
Produtos e/ou serviços de Dr. Reddy’s Laboratories
- Generics: Development, manufacturing, and global commercialization of generic prescription pharmaceuticals including unbranded generic drugs and branded generics across major markets such as North America, India, Europe, and emerging markets across diverse therapeutic areas.
- Active Pharmaceutical Ingredients & Services: Production and worldwide distribution of active pharmaceutical ingredients, custom synthesis, contract development, and research support for generic drug developers and pharmaceutical companies across international commercial markets.
- Biosimilars: In-house development, biologics manufacturing, and global commercialization of biological products and biosimilar monoclonal antibodies, including rituximab and bevacizumab, for oncology and autoimmune indications across India, Europe, and North America.
- Consumer Health: Commercialization and global distribution of over-the-counter prescription-free medicines, dietary nutrition products, wellness treatments, and consumer healthcare solutions sold directly through retail pharmacies, retail outlets, and digital distribution channels.
- Innovative Medicines: Development and commercialization of proprietary specialty formulations, novel chemical entities, and licensed innovative therapeutics focused primarily on oncology and inflammatory conditions through specialized research divisions and global partnerships.
- Vaccines & In-Licensing Partnerships: Commercial promotion and distribution of third-party licensed vaccines, specialized pharmaceuticals, and novel prevention treatments through exclusive distribution partnerships with global biopharmaceutical companies across priority healthcare markets.
equipe executiva do Dr. Reddy’s Laboratories
- Gunupati Venkateswara PrasadCo-Chairman, MD & Member of Management Council
- Kallam Satish ReddyChairman of the Board & Member of the Management Council
- Erez IsraeliCEO & Member of the Management Council
- Mannam VenkatanarasimhamCFO & Member of the Management Council
- Krishna K. VenkateshGlobal Head of IPDO, Integrated Product Development & Member of the Management Council
- Deepak SapraCEO ? API and Services & Member of Management Council
- Motupalli Venkata RamanaCEO of Global Generics & Member of Management Council
- Sanjay SharmaExecutive VP, COO & Member of Management Council
- Patrick AghanianHead of Consumer Health Organization & Member of Management Council
- Bhethanabottla S. PhanimitraChief Digital & Information Officer and Member of the Management Council
Principais indicadores financeiros
Resultados divulgados pela Dr. Reddy’s Laboratories , em INR.
- Cap. de mercado
- 11,5 bi
- Receita (TTM)
- 329,8 bi
- P/L
- 38.2
- LPA (diluído, TTM)
- 0.4
- Dividend yield
- 0.6%
- Margem de lucro
- 8.5%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 353,5 bi | 48,9 bi | 45,1 bi | |
| 325,5 bi | 71,8 bi | 56,5 bi | |
| 279,2 bi | 67,7 bi | 55,7 bi | |
| 245,9 bi | 57,1 bi | 45,1 bi |